Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for Delirium in Hospitalized Elderly
NCT01487317Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2011
- Primary completion
- Aug 2015
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delirium comparing Rivastigmine with Placebo (2 arms). Primary endpoint: Hospital length of stay from randomization to declaration by investigator that patient can leave acute care up to 12 months. Started Jun 2011; status: completed.
02
Drugs
rivastigmine
03
Conditions
delirium
Beyond the preview
Go deeper on NCT01487317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01487317.